10:00:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 Ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3


ListaSpotlight DK
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2023-06-29 08:53:01
  • uPAR-PET with [68]Ga-NOTA-AE105 (now known as uTRACE[®]) was highly prognostic both regarding progression-free survival and overall survival.
  • 94% of glioblastomas (WHO grade 4 gliomas) in the study were uPAR-PET positive underlines validity of using this target for improved diagnosis and categorisation.
  • Together with our recently reported positive preclinical data on therapy with uTREAT[®] in glioblastoma, this strongly supports our ambition to pursue a theranostic approach using uTRACE[®] and uTREAT[®] in glioblastoma patients.

Copenhagen, Denmark, June 29, 2023 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today positive results from the investigator-initiated phase II study using uPAR-PET (uTRACE[®]) in primary brain cancer. The study found that uPAR-PET/MR was a suitable target for the detection and prognosis of primary glioblastomas, the most common type of primary brain cancer.

The investigator-initiated trial tested [68]Ga-NOTA-AE105 uPAR-PET/MR in a total of 24 glioma patients of which 16 (67%) were WHO grade 4 (glioblastomas), 6 (25%) were WHO grade 3 and 2 (8%) were WHO grade 2. Among glioblastoma patients, 94% had uPAR-PET positive tumors. uPAR-PET positivity indicates that a patient may be eligible for future uPAR-targeted radionuclide therapy, e.g. uTREAT[®].

Results from the study, carried out at Rigshospitalet in Copenhagen, will be presented at the World Molecular Imaging Congress (WMIC) in Prague, September 2023.

"We are extremely pleased that the brain cancer study using the uTRACE[®] technology has now reported positive results. Not only does the study demonstrate how uTRACE[®] can be used for tumor characterization and risk stratification that may be used for therapy planning and monitoring. However, most important the study strongly supports our strategy of pursuing the use of uTREAT[®] as therapy in glioblastomas as almost all patients showed clear and substantial uptake of uTRACE[®] that predicts that a similarly uptake of uTREAT[®] will happen", said Ulrich Krasilnikoff, CEO of Curasight. "The prognosis for patients with (glioblastoma) is currently poor, and today's data, combined with our recently announced positive preclinical data of uTREAT[®] therapy in brain cancer support our ambition to pursue a theranostics approach - using uTRACE[®] and uTREAT[®] to improve diagnosis and treatment of this type of aggressive brain cancer."

About high grade glioma and glioblastoma

Treatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Curasight's research and development efforts aim to address this challenge and improve the lives of patients facing aggressive brain cancer. Glioblastoma is the first indication for uTREAT[®], but uTREAT[®] has also potential in several other cancer types expressing the biomarker uPAR. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed with the aggressive form, glioblastoma, annually in the US and EU. Approximately 10% of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive.